These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 21651345

  • 1. End points in irritable bowel syndrome.
    Mangel AW, Fehnel SE.
    Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):293-5. PubMed ID: 21651345
    [No Abstract] [Full Text] [Related]

  • 2. How can we achieve relief of bowel and abdominal symptoms for patients with irritable bowel syndrome with constipation?
    Tack J.
    Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5 Suppl 1):21-6. PubMed ID: 23859757
    [Abstract] [Full Text] [Related]

  • 3. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome?
    Corsetti M, Tack J.
    Neurogastroenterol Motil; 2013 Jun; 25(6):453-7. PubMed ID: 23672677
    [Abstract] [Full Text] [Related]

  • 4. Emerging pharmacological therapies for the irritable bowel syndrome.
    Maneerattanaporn M, Chang L, Chey WD.
    Gastroenterol Clin North Am; 2011 Mar; 40(1):223-43. PubMed ID: 21333909
    [Abstract] [Full Text] [Related]

  • 5. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
    Johnston JM, Shiff SJ, Quigley EM.
    Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
    [Abstract] [Full Text] [Related]

  • 6. Green light from the FDA for new drug development in irritable bowel syndrome and functional dyspepsia.
    Talley NJ.
    Am J Gastroenterol; 2009 Jun; 104(6):1339-41. PubMed ID: 19491845
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome.
    Chang FY, Lu CL, Chen CY, Luo JC.
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2266-72. PubMed ID: 17559369
    [Abstract] [Full Text] [Related]

  • 8. Linaclotide for treatment of irritable bowel syndrome--the view of European regulators.
    Berntgen M, Enzmann H, Schabel E, Prieto Yerro C, Gómez-Outes A, Salmonson T, Musaus J.
    Dig Liver Dis; 2013 Sep; 45(9):724-6. PubMed ID: 23701993
    [No Abstract] [Full Text] [Related]

  • 9. Eluxadoline approved for irritable bowel syndrome with diarrhea.
    Traynor K.
    Am J Health Syst Pharm; 2015 Jul 01; 72(13):1078. PubMed ID: 26092951
    [No Abstract] [Full Text] [Related]

  • 10. The FDA and IBS drug development.
    Mangel AW.
    Am J Gastroenterol; 2009 Dec 01; 104(12):3106; author reply 3106. PubMed ID: 19956135
    [No Abstract] [Full Text] [Related]

  • 11. The Food and Drug Administration approves lubiprostone for irritable bowel syndrome with constipation.
    Lang L.
    Gastroenterology; 2008 Jul 01; 135(1):7. PubMed ID: 18541153
    [No Abstract] [Full Text] [Related]

  • 12. Board Review Vignette: Irritable Bowel Syndrome.
    Talley NJ.
    Am J Gastroenterol; 2016 Sep 01; 111(9):1223-5. PubMed ID: 27527743
    [No Abstract] [Full Text] [Related]

  • 13. Eluxadoline (Viberzi) for irritable bowel syndrome with diarrhea.
    Med Lett Drugs Ther; 2016 Jan 04; 58(1485):4-5. PubMed ID: 26714241
    [No Abstract] [Full Text] [Related]

  • 14. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome.
    Khoshoo V, Armstead C, Landry L.
    Aliment Pharmacol Ther; 2006 Jan 01; 23(1):191-6. PubMed ID: 16393297
    [Abstract] [Full Text] [Related]

  • 15. An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials.
    Macdougall JE, Johnston JM, Lavins BJ, Nelson LM, Williams VS, Carson RT, Shiff SJ, Shi K, Kurtz CB, Baird MJ, Currie MG, Lembo AJ.
    Neurogastroenterol Motil; 2013 Jun 01; 25(6):481-6. PubMed ID: 23384406
    [Abstract] [Full Text] [Related]

  • 16. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
    Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA.
    Am J Gastroenterol; 2005 Jan 01; 100(1):115-23. PubMed ID: 15654790
    [Abstract] [Full Text] [Related]

  • 17. Lubiprostone (Amitiza) for irritable bowel syndrome with constipation.
    Med Lett Drugs Ther; 2008 Jul 14; 50(1290):53-4. PubMed ID: 18617872
    [No Abstract] [Full Text] [Related]

  • 18. Emerging receptor target in the pharmacotherapy of irritable bowel syndrome with constipation.
    Blackshaw LA, Brierley SM.
    Expert Rev Gastroenterol Hepatol; 2013 Jul 14; 7(5 Suppl 1):15-9. PubMed ID: 23859756
    [Abstract] [Full Text] [Related]

  • 19. American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome.
    Chang L, Lembo A, Sultan S.
    Gastroenterology; 2014 Nov 14; 147(5):1149-72.e2. PubMed ID: 25224525
    [No Abstract] [Full Text] [Related]

  • 20. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P, Dapoigny M, Bonaz B, Siproudhis L.
    Aliment Pharmacol Ther; 2005 Feb 15; 21(4):435-44. PubMed ID: 15709995
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.